NEW
HAVEN, Conn., Jan. 30,
2025 /PRNewswire/ -- Trevi Therapeutics,
Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical
company developing the investigational therapy Haduvio™ (oral
nalbuphine ER) for the treatment of patients with chronic cough in
idiopathic pulmonary fibrosis (IPF) and refractory chronic cough
(RCC), today announced that senior management will be attending the
following investor conferences in February.
Piper Sandler Biopharma Mogul Summit
February 2-4, 2025, Park City, Utah
Trevi Representative: Lisa Delfini, Chief Financial
Officer
Oppenheimer Healthcare 2025 Winter CEO & Investor
Summit
February 3-6, 2025,
Vail, Colorado
Trevi Representative: Jennifer
Good, President and CEO
Oppenheimer 35th Annual Healthcare
Life Sciences Virtual Conference
February 11-12, 2025
Corporate Presentation: February
11, 9:20 - 9:50 am ET
Trevi Representatives: Jennifer Good, President and
CEO, and James Cassella, Chief
Development Officer
Register here to watch the live presentation
About Trevi Therapeutics, Inc.
Trevi Therapeutics,
Inc. is a clinical-stage biopharmaceutical company developing the
investigational therapy Haduvio™ (oral nalbuphine extended-release)
for the treatment of chronic cough in patients with idiopathic
pulmonary fibrosis (IPF) and refractory chronic cough (RCC).
Haduvio acts on the cough reflex arc both centrally and
peripherally as a kappa agonist and a mu antagonist (KAMA), which
are opioid receptors that play a key role in controlling cough
hypersensitivity. Nalbuphine is not currently scheduled by the U.S.
Drug Enforcement Agency.
Chronic cough is a highly prevalent disease in IPF patients,
impacting up to 85% of the IPF population. There are ~140,000 U.S.
IPF patients and the impact of chronic cough is significant with
patients coughing up to 1,500 times per day. This consistent cough
and associated damage may lead to worsening disease, a higher risk
of progression, death, or need for lung transplant. Chronic cough
also often leads to a decline in patients' social, physical, and
psychological quality of life. There are no approved therapies for
the treatment of chronic cough in IPF and current off-label
treatment options provide minimal benefit to patients.
Refractory chronic cough affects approximately 2-3 million
adults in the U.S. and is caused by cough reflex hypersensitivity
in both the central and peripheral nerves. It is highly disruptive
and accompanied by a wide range of complications, ranging from
urinary incontinence in females to sleep disruption and social
embarrassment that causes significant social and economic burdens
for patients and those around them. Haduvio is being developed for
the treatment of moderate to severe RCC. There are also no approved
therapies for RCC in the U.S.
Trevi intends to propose Haduvio as the trade name for oral
nalbuphine ER. Its safety and efficacy have not been evaluated by
any regulatory authority.
For more information, visit www.TreviTherapeutics.com and
follow Trevi on X (formerly Twitter) and LinkedIn.
Investor Contact
Jonathan
Carlson
Trevi Therapeutics, Inc.
(203) 654 3286
carlsonj@trevitherapeutics.com
Media Contact
Rosalia
Scampoli
914-815-1465
rscampoli@marketcompr.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/trevi-therapeutics-to-participate-in-upcoming-february-investor-conferences-302363679.html
SOURCE Trevi Therapeutics, Inc.
